



MEDIA CONTACTS

Heather Cox
FierceMarkets, Inc.
202-628-8778 x13
heather@fiercemarkets.com

Rebecca Howe
Genocea Biosciences, Inc.
617-876-8191 x223
Rebecca.Howe@genocea.com

FierceBiotech Names Genocea Biosciences as One of the "Fierce 15" Biotech Companies of 2008

Genocea Biosciences is "Fierce," on Leading Edge of Biotech

CAMBRIDGE, MA – June 24, 2008 – Genocea Biosciences announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Genocea was determined to be one of the "fiercest," proven by their creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.

John Carroll, Editor of FierceBiotech, said, "Working out of his Boston lab, Harvard Medical School's Dr. Darren Higgins is out to create a faster, cheaper, better way to develop new vaccines – mimicking the human immune system in vivo in order to swiftly zero in on the antigens most likely to elicit an immune response. In a breathtakingly short time, the biotech has won a series of kudos from experts in the field and may well change the way vaccines are developed."

"FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole," said Robert Paull, Co-Founder and CEO of Genocea. "Being selected as a member of the 'Fierce 15' is an honor that highlights Genocea Biosciences's potential to make a significant impact in the biotech and global health market."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. The complete list of 'Fierce 15' companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

About FierceMarkets

FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include The Business VoIP Report (<http://www.businessvoipreport.com>), FierceBioResearcher (<http://www.fiercebioresearcher.com>), FierceBiotech (<http://www.fiercebiotech.com>), FierceBroadbandWireless (<http://www.fiercebroadbandwireless.com>), FierceCIO (<http://www.fiercecio.com>), Fierce CIO: Tech Watch (<http://www.fiercecio.com/techwatch>), FierceDeveloper (<http://www.fiercedeveloper.com>), FierceFinance (<http://www.fiercefinance.com>), FierceFinanceIT (<http://www.fiercefinanceit.com>), FierceHealthCare (<http://www.fiercehealthcare.com>), FierceHealthFinance (<http://www.fiercehealthfinance.com>), FierceHealthIT (<http://www.fiercehealthit.com>), FierceIPTV (<http://www.fierceptv.com>), FierceMobileContent (<http://www.fiercemobilecontent.com>), FierceMobileIT (<http://www.fiercemobileit.com>), FierceOnlineVideo (<http://www.fierceonlinevideo.com>), FiercePharma (<http://www.fiercepharma.com>), FierceSarbox (<http://www.fiercesarbox.com>), FierceTelecom (<http://www.fiercetelecom.com>), FierceVaccines (<http://www.fiercevaccines.com>), FierceVoIP (<http://www.fiercevoip.com>), FierceWireless (<http://www.fiercewireless.com>), and FierceWireless: Europe (<http://www.fiercewireless.com/europe>).

About Genocea Biosciences

Genocea Biosciences is commercializing key breakthroughs in vaccine discovery and development. Genocea can rapidly identify antigens that result in the *in vivo* stimulation of protective CD8+ and CD4+ T cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity. Genocea is backed by leading venture capital firms Lux Capital Management and Polaris Venture Partners. Founded in 2006, the company has assembled a world-class team of vaccine experts from Wyeth Vaccines, Merck Vaccines, CSL Ltd., GlaxoSmithKline, Avant Immunotherapeutics, the US National Institutes of Health, and the US Food and Drug Administration. Visit www.genocea.com for more information.

###